Gilead dives deeper into NK cell therapies with Dragonfly deal

Gilead dives deeper into NK cell therapies with Dragonfly deal

Submitted by admin on May 3, 2022 - 10:37am
Source: 
Pharmaforum
News Tags: 
Gilead Sciences
natural killer cells
Dragonfly Therapeutics
TriNKET
cancer
Headline: 
Gilead dives deeper into NK cell therapies with Dragonfly deal
snippet: 

Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics’ TriNKET platform to find therapies for cancer and inflammatory diseases.

Do Not Allow Advertisers to Use My Personal information